If you haven't heard of Rett syndrome, it's probably because it's very rare. Affecting an estimated one in 12,000 baby girls ...

The field of neuroscience has benefited significantly from the groundbreaking work of dedicated researchers who have ...

Phil and Claire Drinkwater have raised more than £11,000 for charity since the loss of their 'joyful' son Jude ...

Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.

Rett syndrome is a neurodevelopmental disorder that primarily affects girls, most of whom have mutations in the transcription regulatory gene MECP2. However, mutations in MECP2 also have been ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

Special Report: Neurotech International has inked a deal with a European leader in development and scale up of cannabis-based ...

D. Boral Capital reaffirmed their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL – Free Report) in a report published on Wednesday morning,Benzinga reports. D. Boral Capital currently has a ...

Romi Loffler fears she will be among the hardest hit by East Renfrewshire Council's decision to means-test and charge for ...

Acadia Pharmaceuticals' forecasted revenues top $1bn in 2025. Find out why ACAD stock is a "Buy" with its profitable outlook ...

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmac ...